Endo acquires rights to Sumavel® DosePro® for $85 million
Endo announced that affiliates of the company have acquired worldwide rights to Sumavel® DosePro® (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix for an upfront payment of $85 million and rights to additional cash payments. April 24, 2014